<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Lamivudine Teva, INN-lamivudine</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.05pt;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.CM39, li.CM39, div.CM39
	{mso-style-name:CM39;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.75pt;
	margin-left:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	mso-style-link:"Title B Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.TitleBChar
	{mso-style-name:"Title B Char";
	mso-style-link:"Title B";
	font-weight:bold;}
p.Char1CharCharCarCarChar, li.Char1CharCharCarCarChar, div.Char1CharCharCarCarChar
	{mso-style-name:"Char1 Char Char Car Car Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Helvetica",sans-serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Helvetica",sans-serif;}
p.Bullet, li.Bullet, div.Bullet
	{mso-style-name:Bullet;
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.55pt;
	text-indent:-14.2pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Withnext, li.Withnext, div.Withnext
	{mso-style-name:"With next";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Action, li.Action, div.Action
	{mso-style-name:Action;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.35pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.9pt 70.55pt 56.9pt 70.55pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>ANNEX
I</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg film-coated
tablets </span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains
100&nbsp;mg lamivudine </span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients see section
6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film-coated tablet </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Orange</span><span lang=EN-GB>, capsule
shaped, biconvex film-coated tablet &#8211; engraved with &#8220;L 100&#8221;
on one side and plain on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva is indicated for the
treatment of chronic hepatitis B in adults with: </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>compensated liver disease with evidence of
active viral replication, persistently elevated serum alanine aminotransferase
(ALT) levels and histological evidence of active liver inflammation and / or
fibrosis. </span><span lang=EN-GB style='color:black'>Initiation of lamivudine
treatment should only be considered when the use of an alternative antiviral
agent with a higher genetic barrier is not available or appropriate (see
section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Therapy with Lamivudine Teva should be
initiated by a physician experienced in the management of chronic hepatitis B. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dosage of Lamivudine Teva
is 100&nbsp;mg once daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Duration of treatment </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The optimal duration of
treatment is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In patients with HBeAg positive chronic
hepatitis B (CHB) without cirrhosis, treatment should be administered for at
least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb
detection) is confirmed, to limit the risk of virological relapse, or until
HBsAg seroconversion </span><span lang=EN-GB>or there is loss of efficacy
(see&nbsp;section&nbsp;4.4). Serum ALT and HBV&nbsp;DNA levels should be
followed regularly after treatment discontinuation to detect any late
virological relapse</span><span lang=EN-GB style='color:black'>.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In patients with HBeAg negative CHB (pre-core
mutant) </span><span lang=EN-GB style='color:black'>without cirrhosis, </span><span
lang=EN-GB>treatment should be administered at least until
HBs&nbsp;seroconversion or there is evidence of loss of efficacy. </span><span
lang=EN-GB style='color:black'>With prolonged treatment, regular reassessment
is recommended to confirm that continuation of the selected therapy remains
appropriate for the patient</span><span lang=EN-GB style='color:black'>.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In patients with cirrhosis and in liver
transplant recipients, treatment cessation is not recommended (see section
5.1). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If lamivudine is discontinued, patients
should be periodically monitored for evidence of recurrent hepatitis (see
section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB
style='color:black'>Clinical resistance </span></i></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>In patients with either HBeAg positive or HBeAg negative
CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant
HBV may result in a diminished therapeutic response to lamivudine, indicated by
a rise in HBV DNA and ALT from previous on-treatment levels. In order to reduce
the risk of resistance in patients receiving lamivudine monotherapy, a switch
to or addition of an alternative agent without cross-resistance to lamivudine
based on therapeutic guidelines should be considered if serum HBV DNA remains detectable
at or beyond 24 weeks of treatment (see section 5.1).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For the treatment of
patients who are co-infected with HIV and are currently receiving or plan to
receive treatment with lamivudine or the combination lamivudine-zidovudine, the
dose of lamivudine prescribed for HIV infection (usually 150&nbsp;mg/twice
daily in combination with other antiretrovirals) should be maintained.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment </span></i></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine serum concentrations (AUC) are
increased in patients with moderate to severe renal impairment due to decreased
renal clearance. The dosage should therefore be reduced for patients with a
creatinine clearance of &lt; 50&nbsp;ml/minute. Lamivudine Teva is not suitable
for patients who require doses below 100&nbsp;mg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Data available in patients undergoing
intermittent haemodialysis (for less than or equal to 4&nbsp;hrs dialysis 2&#8209;3
times weekly), indicate that following the initial dosage reduction of
lamivudine to correct for the patient&#8217;s creatinine clearance, no further
dosage adjustments are required while undergoing dialysis. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Data obtained in patients with hepatic
impairment, including those with end-stage liver disease awaiting transplant,
show that lamivudine pharmacokinetics are not significantly affected by hepatic
dysfunction. Based on these data, no dose adjustment is necessary in patients
with hepatic impairment unless accompanied by renal impairment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In elderly patients, normal ageing with
accompanying renal decline has no clinically significant effect on lamivudine
exposure, except in patients with creatinine clearance of &lt; 50 ml/min.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>The safety and efficacy of Lamivudine Teva in infants,
children and adolescents aged below 18 years have not been established.
Currently available data are described in sections 4.4 and 5.1 but no
recommendation on a posology can be made.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Oral use. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lamivudine Teva can be
taken with or without food.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substance or
to any of the excipients </span><span lang=EN-GB style='color:black'>listed in
section 6.1</span><span lang=EN-GB>. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Lactic acidosis and severe hepatomegaly
with steatosis</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Occurrences of lactic acidosis (in the
absence of hypoxaemia), sometimes fatal, usually associated with severe
hepatomegaly and hepatic steatosis, have been reported with the use of
nucleoside analogues. As <span style='color:black'>lamivudine </span>is a
nucleoside analogue, this risk cannot be excluded. Treatment with nucleoside
analogues should be discontinued when rapidly elevating aminotransferase
levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown
aetiology occur. Benign digestive symptoms, such as nausea, vomiting and
abdominal pain, might be indicative of lactic acidosis development. Severe
cases, sometimes with fatal outcome, were associated with pancreatitis, liver
failure/hepatic steatosis, renal failure and higher levels of serum lactate.
Caution should be exercised when prescribing nucleoside analogues to any patient
(particularly obese women) with hepatomegaly, hepatitis or other known risk
factors for liver disease and hepatic steatosis (including certain medicinal
products and alcohol). Patients co-infected with hepatitis C and treated with
alpha interferon and ribivirin may constitute a special risk. These patients
should be followed closely.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Exacerbations of
hepatitis</span></u></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Exacerbations on
treatment</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Spontaneous
exacerbations in chronic hepatitis B are relatively common and are
characterised by transient increases in serum ALT. After initiating antiviral
therapy, serum ALT may increase in some patients as serum HBV DNA levels
decline. In patients with compensated liver disease, these increases in serum
ALT were generally not accompanied by an increase in serum bilirubin
concentrations or signs of hepatic decompensation.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>HBV viral
subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have
been identified with extended therapy. In some patients the development of YMDD
mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT
elevations and re-emergence of HBV DNA (see section 4.2). In patients who have
YMDD mutant HBV, a switch to or addition of an alternative agent without cross
resistance to lamivudine based on therapeutic guidelines should be considered
(see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Exacerbations after
treatment discontinuation</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Acute exacerbation of
hepatitis has been observed in patients who have discontinued hepatitis B
therapy and is usually </span><span lang=EN-GB style='color:black'>detected by
serum ALT</span><span lang=EN-GB style='color:black'> elevations and </span><span
lang=EN-GB style='color:black'>re-emergence of HBV DNA</span><span lang=EN-GB
style='color:black'>. In the controlled Phase III trials</span><span
lang=EN-GB> <span style='color:black'>with no-active-treatment follow-up, the
incidence of post-treatment ALT elevations (more than 3 times baseline) was
higher in lamivudine-treated patients (21%) compared with those receiving
placebo (8%). However, the proportion of patients who had post-treatment
elevations associated with bilirubin elevations was low and similar in both
treatment arms (see Table 3 in section 5.1). For lamivudine-treated patients,
the majority of post-treatment ALT elevations occurred between 8 and 12 weeks
post-treatment. Most events have been self-limiting, however some fatalities
have been observed. If Lamivudine Teva is discontinued, patients should be
periodically monitored both clinically and by assessment of serum liver
function tests (ALT and bilirubin levels), for at least four months, and then
as clinically indicated. </span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Transplantation
recipients are at greater risk from active viral replication. Due to the
marginal liver function in these patients, hepatitis reactivation at
discontinuation of lamivudine or loss of efficacy during treatment may induce
severe and even fatal decompensation. These patients should be monitored for
clinical, virological and serological parameters associated with hepatitis B,
liver and renal function, and antiviral response during treatment (at least
every month), and, if treatment is discontinued for any reason, for at least 6
months after treatment. Laboratory parameters to be monitored should include
(as a minimum) serum ALT, bilirubin, albumin, blood urea nitrogen, creatinine,
and virological status: HBV antigen/antibody, and serum HBV DNA concentrations when possible. Patients experiencing signs of hepatic insufficiency during or
post-treatment should be monitored more frequently as appropriate.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For patients who
develop evidence of recurrent hepatitis post-treatment, there are insufficient
data on the benefits of re-initiation of lamivudine treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Mitochondrial dysfunction</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Nucleoside and nucleotide analogues have
been demonstrated <i>in vitro</i> and <i>in vivo</i> to cause a variable degree
of mitochondrial damage. There have been reports of mitochondrial dysfunction
in infants exposed in utero and/or post-natally to nucleoside analogues. </span><span
lang=EN-GB>The main adverse events reported are haematological disorders
(anaemia, neutropenia), metabolic disorders (hyperlactatemia, hyperlipasemia). </span><span
lang=EN-GB>Some late-onset neurological disorders have been reported
(hypertonia, convulsion, abnormal behaviour).</span><span lang=EN-GB> The neurological
disorders might be transient or permanent.</span><span lang=EN-GB> Any child
exposed <i>in utero</i> to nucleoside and nucleotide analogues, should have
clinical and laboratory follow-up and should be fully investigated for possible
mitochondrial dysfunction in cases which have relevant signs or symptoms.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Paediatric patients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine has been administered to
children (2 years and above) and adolescents with compensated chronic hepatitis
B. However, due to limitations of the data, the administration of lamivudine to
this patient population is not currently recommended (see section 5.1). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Delta hepatitis or
hepatitis C</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The efficacy of lamivudine in patients
co-infected with Delta hepatitis or hepatitis C has not been established and
caution is advised. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Immunosuppressive
treatments</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Data are limited on the use of lamivudine
in HBeAg negative (pre-core mutant) patients and in those receiving concurrent
immunosuppressive regimes, including cancer chemotherapy. </span><span
lang=EN-GB style='color:black'>Lamivudine should be used with caution in these
patients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Monitoring</span></u></p>

<p class=MsoNormal><span lang=EN-GB>During treatment with Lamivudine Teva
patients should be monitored regularly. Serum ALT </span><span lang=EN-GB
style='color:black'>and HBV DNA</span><span lang=EN-GB> levels should be
monitored at 3 month intervals and </span><span lang=EN-GB style='color:black'>in
HBeAg positive patients</span><span lang=EN-GB> HBeAg should be assessed every
6 months. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>HIV co-infection</span></u></p>

<p class=MsoNormal><span lang=EN-GB>For the treatment of patients who are
co-infected with HIV and are currently receiving or plan to receive treatment
with lamivudine or the combination lamivudine-zidovudine, the dose of
lamivudine prescribed for HIV infection (usually 150&nbsp;mg/twice daily in
combination with other antiretrovirals) should be maintained. For HIV
co-infected patients not requiring anti-retroviral therapy, there is a risk of
HIV mutation when using lamivudine alone for treating chronic hepatitis B.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Transmission of hepatitis B </span></u></p>

<p class=MsoNormal><span lang=EN-GB>There is no information available on
maternal-foetal transmission of hepatitis B virus in pregnant women receiving
treatment with lamivudine. The standard recommended procedures for hepatitis B
virus immunisation in infants should be followed. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be advised that therapy
with lamivudine has not been proven to reduce the risk of transmission of
hepatitis B virus to others and therefore, appropriate precautions should still
be taken. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Interactions with other medicinal
products</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva should not be taken with
any other medicinal products containing lamivudine or medicinal products
containing emtricitabine (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The combination
of lamivudine with cladribine is not recommended (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span style='color:#222222;
background:white'>Excipient(s)</span></u></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i>Sodium</i></p>

<p class=MsoNormal style='line-height:normal'>This medicinal product contains
less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say
essentially &#8220;sodium-free&#8221;.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Interaction studies have only been
performed in adults. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The likelihood of metabolic interactions is
low due to limited metabolism and plasma protein binding and almost complete
renal elimination of unchanged substance. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine is predominantly eliminated by
active organic cationic secretion. The possibility of interactions with other
medicinal products administered concurrently should be considered, particularly
when their main route of elimination is active renal secretion via the organic
cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine,
cimetidine) are eliminated only in part by this mechanism and were shown not to
interact with lamivudine. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Substances shown to be predominately
excreted either via the active organic anionic pathway, or by glomerular
filtration are unlikely to yield clinically significant interactions with
lamivudine. </span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of
trimethoprim/sulphamethoxazole 160&nbsp;mg/800&nbsp;mg increased lamivudine
exposure by about 40&nbsp;%. Lamivudine had no effect on the pharmacokinetics
of trimethoprim or sulphamethoxazole. However, unless the patient has renal
impairment, no dosage adjustment of lamivudine is necessary. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A modest increase in Cmax (28&nbsp;%) was
observed for zidovudine when administered with lamivudine, however overall
exposure (AUC) was not significantly altered. Zidovudine had no effect on the
pharmacokinetics of lamivudine (see section 5.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine has no pharmacokinetic
interaction with alpha-interferon when the two medicinal products are
concurrently administered. There were no observed clinically significant
adverse interactions in patients taking lamivudine concurrently with commonly used
immunosuppressant medicinal products (e.g. cyclosporin A). However, formal
interaction studies have not been performed. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Emtricitabine</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Due to similarities, Lamivudine
Teva should not be administered concomitantly with other cytidine analogues,
such as emtricitabine. Moreover, Lamivudine Teva should not be taken with any
other medicinal products containing lamivudine </span><span lang=EN-GB>(</span><span
lang=EN-GB style='color:black'>see section 4.4)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Cladribine </span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>In vitro</span></i><span
lang=EN-GB style='color:black'> lamivudine inhibits the intracellular
phosphorylation of cladribine leading to a potential risk of cladribine loss of
efficacy in case of combination in the clinical setting. Some clinical findings
also support a possible interaction between lamivudine and cladribine. Therefore,
the concomitant use of lamivudine with cladribine is not recommended (see
section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Sorbitol</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Co-administration of
sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV
daily dose) of lamivudine oral solution resulted in dose-dependent decreases of
14%, 32%, and 36% in lamivudine exposure (AUC</span><sub><span lang=EN-GB
style='font-family:Symbol;color:black'>&yen;</span></sub><span lang=EN-GB
style='color:black'>) and 28%, 52%, and 55% in the Cmax of lamivudine in
adults. When possible, avoid chronic co-administration of Lamivudine Teva with medicinal
products containing sorbitol or other osmotic acting poly-alcohols or
monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider
more frequent monitoring of HBV viral load when chronic co-administration
cannot be avoided. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>A large amount of data on pregnant women
(more than 1000 exposed outcomes) indicate no malformative toxicity. Lamivudine
Teva can be used during pregnancy if clinically needed. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For patients who are
being treated with lamivudine and subsequently become pregnant consideration
should be given to the possibility of a recurrence of hepatitis on
discontinuation of lamivudine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Based on more than 200
mother/child pairs treated for HIV, serum concentrations of lamivudine in
breastfed infants of mothers treated for HIV are very low ( less than 4% of
maternal serum concentrations) and progressively decrease to undetectable
levels when breastfed infants reach 24 weeks of age. The total amount of
lamivudine ingested by a breastfed infant is very low and is therefore likely
to result in exposures exerting a sub-optimal antiviral effect. Maternal
hepatitis B is not a contraindication to breast-feeding if the newborn is
adequately managed for hepatitis B prevention at birth, and there is no evidence
that the low concentration of lamivudine in human milk leads to adverse reactions
in breastfed infants. Therefore breastfeeding may be considered in breast-
feeding mothers being treated with lamivudine for HBV taking into account the
benefit of breast feeding for the child and the benefit of therapy for the
woman. Where there is maternal transmission of HBV, despite adequate
prophylaxis, consideration should be given to discontinuing breastfeeding to
reduce the risk of the emergence of lamivudine resistant mutants in the infant.
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
studies in animals have shown no effect on male or female fertility (see
section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Mitochondrial
dysfunction: </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Nucleoside and
nucleotide analogues have been demonstrated <i>in vitro</i> and <i>in vivo</i>
to cause a variable degree of mitochondrial damage. There have been reports of
mitochondrial dysfunction in infants exposed in utero and/or post-natally to
nucleoside analogues (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Patients should be
informed that malaise and fatigue have been reported during treatment with
lamivudine. The clinical status of the patient and the adverse reaction profile
of lamivudine should be borne in mind when considering the patient's ability to
drive or operate machinery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Summary of the
safety profile</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of adverse reactions and
laboratory abnormalities (with the exception of elevations of ALT and CPK, see
below) were similar between placebo and lamivudine treated patients). The most
common adverse reactions reported were malaise and fatigue, respiratory tract
infections, throat and tonsil discomfort, headache, abdominal discomfort and
pain, nausea, vomiting and diarrhoea. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Tabulated
list of adverse reactions </span></u></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions are listed below by
system organ class and frequency. Frequency categories are only assigned to
those adverse reactions considered to be at least possibly causally related to
lamivudine. Frequencies are defined as: very common (&#8805; 1/10), common
(&#8805; 1/100 to &lt; 1/10), uncommon (&#8805; 1/1000 to &lt; 1/100), rare
(&#8805; 1/10,000 to &lt; 1/1000),very rare (&lt; 1/10,000)<span
style='color:black'> and n</span></span><span lang=EN-GB>ot known (cannot be
estimated from the available data)</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The frequency
categories assigned to the adverse reactions are mainly based on experience
from clinical trials including a total of 1,171 patients with chronic hepatitis
B receiving lamivudine at 100&nbsp;mg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Not known</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Thrombocytopenia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Immune system
  disorders</span></b><span lang=EN-GB style='color:black'>:</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Angioedema</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Hepatobiliary
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Very common</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>ALT</span><span
  lang=EN-GB style='color:black'> elevations (see section 4.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Exacerbations of
  hepatitis, primarily detected by serum ALT elevations, have been reported
  &#8216;on-treatment&#8217; and following lamivudine withdrawal. Most events
  have been self-limited, however fatalities have been observed very rarely
  (see section 4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Skin and
  subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rash, pruritus</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='color:black'>Musculoskeletal
  and connective tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Elevations of CPK</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;Common</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Muscle disorders,
  including myalgia and cramps* </span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="22%" valign=top style='width:22.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Not known</span></p>
  </td>
  <td width="77%" valign=top style='width:77.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Rhabdomyolysis</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='color:black'>* In Phase III studies
frequency observed in the lamivudine treatment group was not greater than
observed in the placebo group</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Paediatric
population </span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Based on limited data
in children aged 2 to 17 years, there were no new safety issues identified
compared to adults.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Other special
populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with HIV infection, cases of
pancreatitis and peripheral neuropathy (or paresthesia) have been reported. In
patients with chronic hepatitis B there was no observed difference in incidence
of these events between placebo and lamivudine treated patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of lactic acidosis, sometimes fatal,
usually associated with severe hepatomegaly and hepatic <br>
steatosis, have been reported with the use of combination nucleoside analogue
therapy in patients with <br>
HIV. There have been rare reports of lactic acidosis in patients receiving
lamivudine for hepatitis B. <br>
<br>
</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals
are asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of lamivudine at very high
dose levels in acute animal studies did not result in any organ toxicity.
Limited data are available on the consequences of ingestion of acute overdoses
in humans. No fatalities occurred, and the patients recovered. No specific
signs or symptoms have been identified following such overdose. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If overdose occurs the patient should be
monitored and standard supportive treatment applied as required. Since
lamivudine is dialysable, continuous haemodialysis could be used in the
treatment of overdose, although this has not been studied. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group - </span><span
lang=EN-GB style='color:black'>Antivirals for systemic use, nucleoside and
nucleotide reverse transcriptase inhibitors,</span><span lang=EN-GB>ATC Code:
J05AF05. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine is an antiviral agent which is
active against hepatitis B virus in all cell lines tested and in experimentally
infected animals. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine is metabolised by both infected
and uninfected cells to the triphosphate (TP) derivative which is the active
form of the parent compound. The intracellular half life of the triphosphate in
hepatocytes is 17&#8209;19 hours <i>in vitro</i>. Lamivudine-TP acts as a
substrate for the HBV viral polymerase.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The formation of further viral DNA is
blocked by incorporation of lamivudine-TP into the chain and subsequent chain
termination. </span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine-TP does not interfere with
normal cellular deoxynucleotide metabolism. It is also only a weak inhibitor of
mammalian DNA polymerases alpha and beta. Furthermore, lamivudine-TP has little
effect on mammalian cell DNA content. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In assays relating to potential substance
effects on mitochondrial structure and DNA content and function, lamivudine
lacked appreciable toxic effects. It has a very low potential to decrease
mitochondrial DNA content, is not permanently incorporated into mitochondrial
DNA, and does not act as an inhibitor of mitochondrial DNA polymerase gamma. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical experience </span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Experience in patients with HBeAg positive CHB and compensated liver
disease </span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In controlled studies, 1 year of lamivudine therapy significantly
suppressed HBV DNA replication [34&#8209;57&nbsp;% of patients were below the
assay detection limits (Abbott Genostics solution hybridization assay, LLOD
&lt; 1.6&nbsp;pg/ml)}, normalised ALT level (40&#8209;72&nbsp;% of patients),
induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss
[by conventional assay], 16&#8209;18&nbsp;% of patients), improved histology
(38&#8209;52&nbsp;% of patients had a &#8805; 2 point decrease in the Knodell
Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3&#8209;17&nbsp;%
of patients) and progression to cirrhosis.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Continued lamivudine treatment for an
additional 2 years in patients who had failed to achieve HBeAg seroconversion
in the initial 1 year controlled studies resulted in further improvement in
bridging fibrosis. In patients with YMDD mutant HBV, 41/82 (50&nbsp;%) patients
had improvement in liver inflammation and 40/56 (71&nbsp;%) patients without
YMDD mutant HBV had improvement. Improvement in bridging fibrosis occurred in
19/30 (63&nbsp;%) patients without YMDD mutant and 22/44 (50&nbsp;%) patients
with the mutant. Five percent (3/56) of patients without the YMDD mutant and
13&nbsp;% (11/82) of patients with YMDD mutant showed worsening in liver
inflammation compared to pre-treatment. Progression to cirrhosis occurred in
4/68 (6&nbsp;%) patients with the YMDD mutant, whereas no patients without the mutant
progressed to cirrhosis. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In an extended treatment study in Asian
patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at
the end of the 5 year treatment period was 48&nbsp;% (28/58) and 47&nbsp;%
(15/32), respectively. HBeAg seroconversion was increased in patients with
elevated ALT levels; 77&nbsp;% (20/26) of patients with pre-treatment ALT &gt;
2 x ULN seroconverted. At the end of 5 years, all patients had HBV DNA levels
that were undetectable or lower than pre-treatment levels. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Further results from the trial by YMDD mutant
status are summarised in Table 1. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 1: Efficacy results 5 years by
YMDD status (Asian Study) NUCB3018 </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:23.15pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
  lang=EN-GB style='color:black'>Subjects,&nbsp;% (no.)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><i><span
  lang=EN-GB style='color:black'>YMDD mutant HBV status</span></i></b></p>
  </td>
  <td width=91 valign=top style='width:68.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>YMDD<sup>1</sup></span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Non-YMDD<sup>1</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><u><span
  lang=EN-GB style='color:black'>HBeAg seroconversion</span></u></b></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
  lang=EN-GB style='color:black'>&nbsp;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>- All patients </span></p>
  <p class=MsoNormal><span lang=EN-GB>- Baseline ALT &#8804; 1 x ULN</span><sup><span
  lang=EN-GB style='font-size:7.0pt'>2</span></sup><span lang=EN-GB
  style='font-size:7.0pt'> </span></p>
  <p class=MsoNormal><span lang=EN-GB>- Baseline ALT &gt; 2 x ULN</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
  lang=EN-GB style='color:black'>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><u><span
  lang=EN-GB style='color:black'>Undetectable HBV DNA</span></u></b><u><span
  lang=EN-GB style='color:black'> </span></u></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><u><span
  lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=MsoNormal><span lang=EN-GB>- Baseline<sup>3</sup></span><span
  lang=EN-GB style='font-size:7.0pt'> </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>- Week 260<sup>4</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;&nbsp; negative </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;&nbsp; positive &lt; baseline </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;&nbsp; positive &gt; baseline</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><u><span
  lang=EN-GB style='color:black'>ALT normalisation</span></u></b></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>- </span></b><span lang=EN-GB>Baseline
  </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp; normal </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp; above normal </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>- </span></b><span lang=EN-GB>Week 260
  </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp; normal&nbsp;&nbsp;&nbsp; </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp; above normal &lt;
  baseline&nbsp;&nbsp;&nbsp; </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp; above normal &gt; baseline</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=91 valign=top style='width:68.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>38&nbsp; (15/40)</span></p>
  <p class=MsoNormal><span lang=EN-GB>9&nbsp;&nbsp;&nbsp;&nbsp; (1/11)</span></p>
  <p class=MsoNormal><span lang=EN-GB>60&nbsp;&nbsp; (9/15)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;text-autospace:
  none'><span lang=EN-GB style='font-size:12.0pt;color:black'>5<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:12.0pt;color:black'>(2/40)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  (2/25)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>92&nbsp;&nbsp; (23/25)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>0</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>28&nbsp;&nbsp; (11/40)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>73&nbsp;&nbsp; (29/40)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>46&nbsp;&nbsp; (13/28)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>21&nbsp;&nbsp;&nbsp; (6/28)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>32&nbsp;&nbsp;&nbsp; (9/28)</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB>72&nbsp;&nbsp;&nbsp; (13/18)</span></p>
  <p class=MsoNormal><span lang=EN-GB>33&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;(2/6)</span></p>
  <p class=MsoNormal><span lang=EN-GB>100&nbsp; (11/11)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;text-autospace:
  none'><span lang=EN-GB style='font-size:12.0pt;color:black'>6<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:12.0pt;color:black'>(1/18)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>0</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>100&nbsp;&nbsp;&nbsp; (4/4)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>0</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>33&nbsp;&nbsp;&nbsp;&nbsp; (6/18)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>67&nbsp;&nbsp;&nbsp; (12/18)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (2/4)</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>0</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;color:black'>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (2/4)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:8.0pt'>1 Patients designated as YMDD mutant were those with
&#8805;5&nbsp;% YMDD mutant HBV at any annual time-point during the 5-year
period. Patients categorised as non-YMDD mutant were those with &gt; 95&nbsp;%
wild-type HBV at all annual time-points during the 5-year study period </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:8.0pt'>2 Upper limit of normal </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:8.0pt'>3 Abbott Genostics solution hybridisation assay (LLOD
&lt; 1.6&nbsp;pg/ml </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR style='font-size:
8.0pt'>4 Chiron Quantiplex assay (LLOD 0.7&nbsp;Meq/ml) </span></p>

<p class=MsoNormal><span lang=FR style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Comparative data according to YMDD status
were also available for histological assessment but only up to three years. In
patients with YMDD mutant HBV, 18/39 (46&nbsp;%) had improvements in
necroinflammatory activity and 9/39 (23&nbsp;%) had worsening. In patients
without the mutant, 20/27 (74&nbsp;%) had improvements in necroinflammatory
activity and 2/27 (7&nbsp;%) had worsening. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following HBeAg seroconversion, serologic
response and clinical remission are generally durable after stopping
lamivudine. However, relapse following seroconversion can occur. In a long-term
follow-up study of patients who had previously seroconverted and discontinued
lamivudine, late virological relapse occurred in 39&nbsp;% of the subjects.
Therefore, following HBeAg seroconversion, patients should be periodically
monitored to determine that serologic and clinical responses are being
maintained. In patients who do not maintain a sustained serological response,
consideration should be given to retreatment with either lamivudine or an
alternative antiviral agent for resumption of clinical control of HBV. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients followed for up to 16 weeks
after discontinuation of treatment at one year, post-treatment ALT elevations
were observed more frequently in patients who had received lamivudine than in
patients who had received placebo. A comparison of post-treatment ALT
elevations between weeks 52 and 68 in patients who discontinued lamivudine at
week 52 and patients in the same studies who received placebo throughout the
treatment course is shown in Table 2. The proportion of patients who had
post-treatment ALT elevations in association with an increase in bilirubin
levels was low and similar in patients receiving either lamivudine or placebo. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 2: Post-treatment ALT Elevations
in 2 Placebo-Controlled Studies in Adults </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=626
 style='width:469.75pt;border-collapse:collapse'>
 <tr style='height:25.25pt'>
  <td width=319 rowspan=2 valign=bottom style='width:239.25pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.25pt'>
  <p class=MsoNormal><span lang=EN-GB>Abnormal Value </span></p>
  </td>
  <td width=307 colspan=2 valign=top style='width:230.5pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Patients
  with ALT Elevation/ </span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Patients
  with Observations*</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=154 style='width:115.25pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Lamivudine</span></p>
  </td>
  <td width=154 style='width:115.4pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Placebo</span></p>
  </td>
 </tr>
 <tr style='height:13.25pt'>
  <td width=319 style='width:239.25pt;border:solid black 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt;height:13.25pt'>
  <p class=MsoNormal><span lang=EN-GB>ALT &#8805; 2 x baseline value </span></p>
  </td>
  <td width=154 style='width:115.25pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>37/137
  (27&nbsp;%)</span></p>
  </td>
  <td width=154 style='width:115.4pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.25pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='color:black'>22/116 (19&nbsp;%) </span></p>
  </td>
 </tr>
 <tr style='height:13.25pt'>
  <td width=319 valign=top style='width:239.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.25pt'>
  <p class=MsoNormal><span lang=EN-GB>ALT &#8805; 3 x baseline value</span><span
  lang=EN-GB style='font-size:7.0pt'>&#8224; </span></p>
  </td>
  <td width=154 valign=top style='width:115.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>29/137
  (21&nbsp;%)</span></p>
  </td>
  <td width=154 valign=top style='width:115.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.25pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9/116
  (8&nbsp;%)</span></p>
  </td>
 </tr>
 <tr style='height:25.9pt'>
  <td width=319 valign=top style='width:239.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.9pt'>
  <p class=MsoNormal><span lang=EN-GB>ALT &#8805; 2 x baseline value and
  absolute ALT &gt; 500 IU/l </span></p>
  </td>
  <td width=154 valign=bottom style='width:115.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>21/137
  (15&nbsp;%)</span></p>
  </td>
  <td width=154 valign=bottom style='width:115.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.9pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>8/116
  (7&nbsp;%)</span></p>
  </td>
 </tr>
 <tr style='height:27.75pt'>
  <td width=319 valign=top style='width:239.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=MsoNormal><span lang=EN-GB>ALT &#8805;2 x baseline value; and
  bilirubin &gt;2 x ULN and &#8805;2 x baseline value </span></p>
  </td>
  <td width=154 valign=bottom style='width:115.25pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1/137
  (0.7&nbsp;%)</span></p>
  </td>
  <td width=154 valign=bottom style='width:115.4pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1/116
  (0.9&nbsp;%)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>*Each patient may be represented in one or
more category.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB style='position:relative;top:-5.0pt'>&#8224;</span></sup><span
lang=EN-GB>Comparable to a Grade 3 toxicity in accordance with modified WHO
criteria. </span></p>

<p class=MsoNormal><span lang=EN-GB>ULN = Upper limit of normal. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Experience in patients with HBeAg
negative CHB: </span></i></p>

<p class=MsoNormal><span lang=EN-GB>Initial data indicate the efficacy of
lamivudine in patients with HBeAg negative CHB is similar to patients with
HBeAg positive CHB, with 71&nbsp;% of patients having HBV DNA suppressed below
the detection limit of the assay, 67&nbsp;% ALT normalisation and 38&nbsp;%
with improvement in HAI after one year of treatment. When lamivudine was
discontinued, the majority of patients (70&nbsp;%) had a return of viral
replication. Data is available from an extended treatment study in HBeAg
negative patients (NUCAB3017) treated with lamivudine. After two years of
treatment in this study, ALT normalisation and undetectable HBV DNA occurred in
30/69 (43&nbsp;%) and 32/68 (47&nbsp;%) patients respectively and improvement
in necroinflammatory score in 18/49 (37&nbsp;%) patients. In patients without
YMDD mutant HBV, 14/22 (64&nbsp;%) showed improvement in necroinflammatory
score and 1/22 (5&nbsp;%) patients worsened compared to pre-treatment. In
patients with the mutant, 4/26 (15&nbsp;%) patients showed improvement in
necroinflammatory score and 8/26 (31&nbsp;%) patients worsened compared to
pre-treatment. No patients in either group progressed to cirrhosis. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Frequency of emergence of YMDD mutant
HBV and impact on the treatment response:</span></i><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine monotherapy results in the
selection of YMDD mutant HBV in approximately 24&nbsp;% of patients following
one year of therapy, increasing to 69&nbsp;% following 5 years of therapy.
Development of YMDD mutant HBV is associated with reduced treatment response in
some patients, as evidenced by increased HBV DNA levels and ALT elevations from
previous on-therapy levels, progression of signs and symptoms of hepatitis
disease and/or worsening of hepatic necroinflammatory findings. Given the risk
of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in
patients with detectable serum HBV DNA at or beyond 24 weeks of treatment (see
section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a retrospective study to determine the
factors associated with HBV DNA breakthrough, 159 Asian HBeAg-positive patients
were treated with lamivudine and followed up for a median period of almost 30
months. Those with HBV DNA levels greater than 200 copies/mL at 6 months (24
weeks) of lamivudine therapy had a 60&nbsp;% chance of developing the YMDD
mutant compared with 8&nbsp;% of those with HBV DNA levels less than
200&nbsp;copies/mL at 24 weeks of lamivudine therapy. The risk for developing
YMDD mutant was 63% versus 13% with a cut off of 1000 copies/ml (NUCB3009 and
NUCB3018).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Experience in
patients with decompensated liver disease</span></i><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Placebo
controlled studies have been regarded as inappropriate in patients with
decompensated liver disease, and have not been undertaken. In non&#8209;controlled
studies, where lamivudine was administered prior to and during transplantation,
effective HBV DNA suppression and ALT normalisation was demonstrated. When
lamivudine therapy was continued post transplantation there was reduced graft
re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76&#8209;100&nbsp;%.
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>As anticipated
due to the concomitant immunosuppression, the rate of emergence of YMDD mutant HBV
after 52 weeks treatment was higher (36&nbsp;%&#8209;64&nbsp;%) in the liver
transplant population than in the immunocompetent CHB patients (14&nbsp;%&#8209;32&nbsp;%).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Experience in CHB patients with advanced
fibrosis or cirrhosis</span></i><span lang=EN-GB>: </span></p>

<p class=MsoNormal><span lang=EN-GB>In a placebo-controlled study in 651
patients with clinically compensated chronic hepatitis B and histologically
confirmed fibrosis or cirrhosis, lamivudine treatment (median duration 32
months) significantly reduced the rate of overall disease progression (34/436,
7.8&nbsp;% for lamivudine versus 38/215, 17.7&nbsp;% for placebo, p=0.001),
demonstrated by a significant reduction in the proportion of patients having
increased Child-Pugh scores (15/436, 3.4&nbsp;% versus 19/215, 8.8&nbsp;%,
p=0.023) or developing hepatocellular carcinoma (17/436, 3.9&nbsp;% versus
16/215, 7.4&nbsp;%, p=0.047). The rate of overall disease progression in the
lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA
(23/209, 11&nbsp;%) compared to those without detectable YMDD mutant HBV
(11/221, 5&nbsp;%). However, disease progression in YMDD subjects in the
lamivudine group was lower than the disease progression in the placebo group
(23/209, 11&nbsp;% versus 38/214, 18&nbsp;% respectively). Confirmed HBeAg
seroconversion occurred in 47&nbsp;% (118/252) of subjects treated with
lamivudine and 93&nbsp;% (320/345) of subjects receiving lamivudine became HBV
DNA negative (VERSANT [version 1], bDNA assay, LLOD &lt; 0.7&nbsp;MEq/ml)
during the study. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Experience in children and adolescents</span></i><span
lang=EN-GB>: </span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine has been administered to
children and adolescents with compensated CHB in a placebo controlled study of
286 patients aged 2 to 17 years. This population primarily consisted of
children with minimal hepatitis B. A dose of 3&nbsp;mg/kg once daily (up to a
maximum of 100&nbsp;mg daily) was used in children aged 2 to 11 years and a
dose of 100&nbsp;mg once daily in adolescents aged 12 years and above. This
dose needs to be further substantiated. The difference in the HBeAg
seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between
placebo and lamivudine was not statistically significant in this population
(rates after one year were 13&nbsp;% (12/95) for placebo versus 22&nbsp;% (42/191)
for lamivudine; p=0.057). The incidence of YMDD mutant HBV was similar to that
observed in adults, ranging from 19&nbsp;% at week 52 up to 45&nbsp;% in
patients treated continuously for 24 months.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine is well absorbed from the
gastrointestinal tract, and the bioavailability of oral lamivudine in adults is
normally between 80 and 85&nbsp;%. Following oral administration, the mean time
(t</span><span lang=EN-GB style='font-size:7.0pt'>max</span><span lang=EN-GB>)
to maximal serum concentrations (C</span><span lang=EN-GB style='font-size:
7.0pt'>max</span><span lang=EN-GB>) is about an hour. At therapeutic dose
levels i.e. 100&nbsp;mg once daily, C</span><span lang=EN-GB style='font-size:
7.0pt'>max</span><span lang=EN-GB> is in the order of 1.1&#8209;1.5&nbsp;&micro;g/ml
and trough levels were 0.015&#8209;0.020&nbsp;&micro;g/ml. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co-administration of lamivudine with food
resulted in a delay of t</span><span lang=EN-GB style='font-size:7.0pt'>max</span><span
lang=EN-GB> and a lower C</span><span lang=EN-GB style='font-size:7.0pt'>max</span><span
lang=EN-GB> (decreased by up to 47&nbsp;%). However, the extent (based on the
AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be
administered with or without food. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u><span lang=EN-GB>
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>From intravenous studies the mean volume of
distribution is 1.3&nbsp;l/kg. Lamivudine exhibits linear pharmacokinetics over
the therapeutic dose range and displays low plasma protein binding to albumin. </span></p>

<p class=MsoNormal><span lang=EN-GB>Limited data shows lamivudine penetrates
the central nervous system and reaches the cerebro-spinal fluid (CSF). The mean
lamivudine CSF/serum concentration ratio 2&#8209;4 hours after oral
administration was approximately 0.12. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Biotransformation</span></u><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine is predominately cleared by
renal excretion of unchanged substance. The likelihood of metabolic substance
interactions with lamivudine is low due to the small (5&#8209;10&nbsp;%) extent
of hepatic metabolism and the low plasma protein binding. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The mean systemic clearance of lamivudine
is approximately 0.3&nbsp;l/h/kg. The observed half-life of elimination is 5 to
7 hours. The majority of lamivudine is excreted unchanged in the urine via
glomerular filtration and active secretion (organic cationic transport system).
Renal clearance accounts for about 70&nbsp;% of lamivudine elimination. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Studies in patients with renal impairment
show lamivudine elimination is affected by renal dysfunction. Dose reduction in
patients with a creatinine clearance of &lt; 50&nbsp;ml/min is necessary (see
section 4.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pharmacokinetics of lamivudine are
unaffected by hepatic impairment. Limited data in patients undergoing liver
transplantation show that impairment of hepatic function does not impact
significantly on the pharmacokinetics of lamivudine unless accompanied by renal
dysfunction. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In elderly patients the pharmacokinetic
profile of lamivudine suggests that normal ageing with accompanying renal
decline has no clinically significant effect on lamivudine exposure, except in
patients with creatinine clearance of &lt; 50&nbsp;ml/min (see section 4.2). </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of lamivudine in animal
toxicity studies at high doses was not associated with any major organ
toxicity. At the highest dosage levels, minor effects on indicators of liver
and kidney function were seen together with occasional reduction in liver
weights. Reduction of erythrocytes and neutrophil counts were identified as the
effects most likely to be of clinical relevance. These events were seen
infrequently in clinical studies. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine was not mutagenic in bacterial
tests but, like many nucleoside analogues showed activity in an <i>in vitro</i>
cytogenetic assay and the mouse lymphoma assay. Lamivudine was not genotoxic <i>in
vivo </i>at doses that gave plasma concentrations around 60&#8209;70 times
higher than the anticipated clinical plasma levels. As the <i>in vitro</i>
mutagenic activity of lamivudine could not be confirmed by <i>in vivo</i>
tests, it is concluded that lamivudine should not represent a genotoxic hazard
to patients undergoing treatment. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reproductive studies in animals have not
shown evidence of teratogenicity and showed no effect on male or female
fertility. Lamivudine induces early embryolethality when administered to
pregnant rabbits at exposure levels comparable to those achieved in man, but
not in the rat even at very high systemic exposures. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The results of long term carcinogenicity
studies with lamivudine in rats and mice did not shown any carcinogenic
potential. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal><span lang=EN-GB>Sodium starch glycolate (Type A)</span></p>

<p class=MsoNormal><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Tablet film coat</span></u></p>

<p class=MsoNormal><span lang=NL>Hypromellose 3cP</span></p>

<p class=MsoNormal><span lang=NL>Hypromellose 6cP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NL>Titanium dioxide </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Macrogol 400</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate 80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iron oxide
yellow </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iron oxide red </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2 years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
PVC/PVdC &#8211; Aluminium blisters </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack sizes of
28, 30, 84 or 100 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Containers:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE tablet containers with white opaque polyethylene child resistent screw cap
with induction seal </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of 60
film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE tablet containers with white opaque polypropylene child resistent,
tamper-evident screw cap with induction seal</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of 60 film-coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
disposal</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused </span><span lang=EN-GB
style='color:black'>medicinal </span><span lang=EN-GB>product or waste material
should be disposed of in accordance with local requirements. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=DE>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/566/001&#8211;
28 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/566/002
&#8211; 30 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/566/003
&#8211; 84 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/566/004
&#8211; 100 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/09/566/005
&#8211; 60 Tablets (bottle)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/09/566/006 &#8211;
60 Tablets </span>(bottle with tamper evident cap)</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 23 October 2009</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 09 September 2014 </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a><span
style='color:black'> </span></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><u><span lang=EN-GB style='font-size:10.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><u><span
lang=EN-GB style='font-size:10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:84.9pt;margin-bottom:.0001pt;text-indent:-35.25pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS </span></b><b><span
style='layout-grid-mode:line'>OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:84.9pt;margin-bottom:.0001pt;text-indent:-35.25pt'><b><span
style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:84.9pt;margin-bottom:.0001pt;text-indent:-35.25pt'><b><span
style='layout-grid-mode:line'>C. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS</span></b><b><span style='font-family:"TimesNewRoman,Bold",serif;
layout-grid-mode:line'> </span></b><b><span lang=EN-GB>AND REQUIREMENTS OF </span></b><b><span
style='layout-grid-mode:line'>THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:84.9pt;margin-bottom:.0001pt;text-indent:-35.25pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:84.9pt;margin-bottom:.0001pt;text-indent:-35.25pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:70.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Teva Pharmaceutical Works Private Limited
Company</span></p>

<p class=MsoNormal><span lang=EN-GB>Pallagi &uacute;t 13</span></p>

<p class=MsoNormal><span lang=EN-GB>Debrecen</span><span lang=EN-GB> H-4042</span></p>

<p class=MsoNormal><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>Pharmachemie B.V.</span></p>

<p class=MsoNormal>Swensweg 5</p>

<p class=MsoNormal>2031 GA Haarlem</p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Teva Operations
Poland Sp.z o. o.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Mogilska 80
Str.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>31-546
Krak&oacute;w</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Poland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription </span><span lang=EN-GB>(See Annex I: Summary of Product
Characteristics, section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF </span><span style='layout-grid-mode:line'>THE
MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Report</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='color:black'>The requirements for submission of periodic safety update
reports for this medicinal products are set out in the list of Union reference
dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC
and any subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;font-family:"Tms Rmn",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;font-family:"Tms Rmn",serif'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>carton</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg film&#8209;coated
tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 100&nbsp;mg
of lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blisters:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>28 film-coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>30 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>84 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#A0A0A0'>100 film-coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span><span
lang=EN-GB>SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>EU/1/09/566/001<span
style='background:lightgrey'>&#8211; 28 Tablets</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
lightgrey'>EU/1/09/566/002 &#8211; 30 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE style='background:
lightgrey'>EU/1/09/566/003 &#8211; 84 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>EU/1/09/566/004 &#8211; 100 Tablets</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>2D
barcode carrying the unique identifier included.</span><span lang=EN-GB
style='color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
  BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>Immediate packaging (blister foil)</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg film&#8209;coated
tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TEVA B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>Tablet container</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg film&#8209;coated
tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film&#8209;coated tablet contains 100&nbsp;mg
of lamivudine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Tablet container:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60 film-coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span></b><b><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/09/566/005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>EU/1/09/566/006 </span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Outer
packaging (carton):</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Immediate
packaging (bottle label):</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>In case no
outer packaging is used</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva 100&nbsp;mg</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Outer
packaging (carton):</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>2D
barcode carrying the unique identifier included.</span><span lang=EN-GB
style='color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Immediate
packaging (bottle label):</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>In case no
outer packaging is used</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>&lt;2D
barcode carrying the unique identifier included.&gt;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Outer
packaging (carton):</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:lightgrey'>Immediate packaging (bottle label):</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='background:lightgrey'>In case no outer packaging is used</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&lt;PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>NN:&gt;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:12.0pt'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='color:black'>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Lamivudine Teva 100&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>lamivudine</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine </span><span
lang=EN-GB style='color:black'>because it contains important information for
you</span><span lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any of the side effects </span><span
lang=EN-GB style='color:black'>talk to your doctor or pharmacist. This includes
</span><span lang=EN-GB>any possible side effects not listed in this leaflet.
See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Lamivudine Teva is and
what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>What you need to know </span><span lang=EN-GB>before you
take Lamivudine Teva</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Lamivudine Teva</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in;line-height:normal'><span
lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to store Lamivudine Teva</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other</span><span lang=EN-GB>
information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Lamivudine Teva is and what it is
used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The active ingredient in Lamivudine Teva is
lamivudine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lamivudine
Teva is used to treat long term (chronic) hepatitis B infection in adults.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>Lamivudine Teva
</span><span lang=EN-GB>is an antiviral medicine that suppresses the hepatitis
B virus and belongs to a group of medicines called <i>nucleoside analogue
reverse transcriptase inhibitors (NRTIs)</i>.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>Hepatitis B is
a virus that infects the liver </span><span lang=EN-GB>causes long term
(chronic) infection, and can lead to liver damage. Lamivudine Teva <span
style='color:black'>can be used in people whose liver is damaged but still
functions </span>normally<span style='color:black'> (<i>compensated liver
disease</i>).</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>Treatment with
Lamivudine Teva can reduce the amount of hepatitis B virus in your body. This
should lead to a reduction in liver damage and an improvement in your liver
function. </span><span lang=EN-GB style='color:black'>Not everyone responds to
treatment with Lamivudine Teva in the same way. Your doctor will monitor the
effectiveness of your treatment with regular blood tests.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB style='color:black'>What you need to know
</span><span lang=EN-GB>before you take Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are <b>allergic </b>to lamivudine or any
of the other ingredients of </span><span lang=EN-GB style='color:black'>this
medicine </span><i><span lang=EN-GB>(listed in Section 6).</span></i></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=EN-GB>Check
with your doctor</span></b><span lang=EN-GB> if you think this applies to you.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Some people taking Lamivudine Teva or other similar medicines are
more at risk of serious side effects. You need to be aware of the extra risks:</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had other types of <b>liver
disease</b>, such as hepatitis C.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are seriously <b>overweight</b>
(especially if you are a woman).</span></p>

<p class=Action style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:normal'><span
lang=EN-GB style='font-family:Wingdings'>&egrave;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>Talk to your doctor if any of these apply to
you</span></b><span lang=EN-GB>. You may need extra check-ups, including blood
tests, while you are taking your medication. <b>See Section 4 </b>for more
information about the risks. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB>Do not stop
taking Lamivudine Teva</span></b><span lang=EN-GB> without your doctor&#8217;s
advice, as there is a risk of your hepatitis getting worse. When you stop
taking Lamivudine Teva your doctor will monitor you for at least four months to
check for any problems. This will mean taking blood samples to check for any raised
liver enzyme levels, which may indicate liver damage.</span><span lang=EN-GB
style='color:black'> See section 3 for more information about how to take </span><span
lang=EN-GB>Lamivudine Teva</span><span lang=EN-GB style='color:black'>.</span></p>

<h2><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-style:normal'>Look out for important symptoms</span></h2>

<p class=MsoNormal><span lang=EN-GB>Some people taking medicines for hepatitis
B infection develop other conditions, which can be serious. You need to know
about important signs and symptoms to look out for while you are taking
Lamivudine Teva.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Wingdings;color:black'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Read
the information &#8216;Other possible side effects of therapy for Hepatitis
B&#8217; in Section&nbsp;4 of this leaflet.</span></p>

<h2><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-style:normal'>Protect other people</span></h2>

<p class=MsoNormal><span lang=EN-GB>Hepatitis B infection is spread by sexual
contact with someone who has the infection, or by transfer of infected blood
(for example, by sharing injection needles). Lamivudine Teva will not stop you
passing hepatitis B infection on to other people. To protect other people from
becoming infected with hepatitis B:</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:normal'><span
lang=EN-GB style='font-size:12.0pt;font-family:Wingdings;color:black'>&#159;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Use a condom</span></b><span lang=EN-GB> when you have oral or
penetrative sex.</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:normal'><span
lang=EN-GB style='font-size:12.0pt;font-family:Wingdings;color:black'>&#159;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><b><span
lang=EN-GB>Do not risk blood transfer</span></b><span lang=EN-GB> &#8212; for
example, do not share needles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:-1.7pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, </span><span
lang=EN-GB>have recently taken or might take</span><span lang=EN-GB> any other
medicines, including herbal medicines or other medicines you bought without a
prescription. </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:-1.7pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt;line-height:normal'><span
lang=EN-GB>Remember to tell your doctor or pharmacist if you begin taking a new
medicine while you are taking Lamivudine Teva.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB
style='color:black'>These medicines should not be used with </span><span
lang=EN-GB>Lamivudine Teva</span><span lang=EN-GB style='color:black'>:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.7pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>medicines (usually liquids)
containing sorbitol and other sugar alcohols (such as xylitol, mannitol,
lactitol or maltitol), if taken regularly</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.7pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>other medicines containing lamivudine,
used to treat HIV infection </span><span lang=EN-GB>(sometimes called the AIDS
virus)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.7pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>emtricitabine (used to treat
HIV or hepatitis B infection)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.7pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>cladribine, used to treat <b>hairy
cell leukaemia</b></span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=EN-GB>Tell
your doctor</span></b><span lang=EN-GB> if you are being treated with any of
these.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant, </span><span lang=EN-GB style='color:black'>think you may be </span><span
lang=EN-GB>pregnant,<span style='color:black'> </span>or are planning to have a
baby:</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=EN-GB>Talk
to your doctor </span></b><span lang=EN-GB>about the risks and benefits of
taking Lamivudine Teva during your pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop
treatment with Lamivudine Teva without your doctor&#8217;s advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB
style='color:black'>Breast-feeding</span></b><span lang=EN-GB style='color:
black'> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Lamivudine Teva</span><span lang=EN-GB style='color:black'> can pass
into breast-milk. If you are breast-feeding, </span><span lang=EN-GB>or
thinking about breast-feeding:</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-family:Wingdings;color:black'>&egrave;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>Talk to your doctor </span></b><span
lang=EN-GB>before you take Lamivudine Teva.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Lamivudine Teva </span><span lang=EN-GB>may make you feel
tired, which could <span style='color:black'>affect your ability to drive or
use machines</span>. </span></p>

<p class=Action style='margin-top:0in;margin-right:-1.7pt;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:normal'><span
lang=EN-GB style='font-family:Wingdings'>&egrave;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Don&#8217;t drive or use machines unless you are
sure you&#8217;re not affected.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lamivudine
Teva</span></b><b> contains sodium</b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains less than
1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially
&#8220;sodium-free&#8221;.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take Lamivudine Teva </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you to</span></b><span
lang=EN-GB>. Check with your doctor or pharmacist if you are not sure. </span></p>

<h2><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-style:normal'>Stay in regular contact with your doctor</span></h2>

<p class=MsoNormal><span lang=EN-GB>Lamivudine Teva helps to control your
hepatitis B infection. You need to keep taking it every day to control your
infection and stop your illness getting worse.</span></p>

<p class=Action style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt'><span lang=EN-GB
style='font-family:Wingdings'>&egrave;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>Keep in touch with your doctor, and do not
stop taking Lamivudine Teva</span></b><span lang=EN-GB> without your
doctor&#8217;s advice.</span></p>

<h2><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-style:normal'>How much to take</span></h2>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>The usual dose
of Lamivudine Teva is one tablet (100&nbsp;mg lamivudine) once a day. </span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor may prescribe a lower dose if you have problems with your
kidneys. An <span style='color:black'>oral solution</span> of Lamivudine is
available for people who need a lower than usual dose, or who can&#8217;t take
tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Wingdings'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=EN-GB
style='color:black'>Talk to your doctor </span></b><span lang=EN-GB
style='color:black'>if this applies to you.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
already taking another medicine that contains lamivudine for HIV infection,
your doctor will continue to treat you with the higher dose, (usually
150&nbsp;mg twice a day), because the dose of lamivudine in Lamivudine Teva
(100&nbsp;mg) is not enough to treat HIV infection. If you are planning to
change your HIV treatment, discuss this change with your doctor first.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow the tablet whole, with some water. Lamivudine
Teva can be taken with or without food.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you take more Lamivudine Teva than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Accidentally
taking too much Lamivudine Teva is unlikely to cause any serious problems.</span><span
lang=EN-GB> If you accidentally take too much, tell your doctor or pharmacist,
or contact your nearest hospital emergency department for further advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you forget to take a dose, take it as soon as you remember. Then
continue </span><span lang=EN-GB>your treatment as before.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not take a double dose to make up for a missed dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Do not stop taking Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>You must not
stop taking Lamivudine Teva without consulting your doctor. </span><span
lang=EN-GB>There is a risk of your hepatitis getting worse (see section 2).<span
style='color:black'> When you stop taking Lamivudine Teva your doctor will
monitor you for at least four months to check for any problems. This will mean
taking blood samples to check for any raised liver enzyme levels, which may
indicate liver damage.</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Like all medicines, this
medicine can cause side effects, but not everyone gets them. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>As well as
the side effects listed below for Lamivudine Teva</span></b><span lang=EN-GB>,
other conditions can develop during therapy for&nbsp;hepatitis B. </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>It
is important to read the information under &#8216;Other possible side effects
of therapy for&nbsp;hepatitis B&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Side effects that were
commonly reported in Lamivudine clinical trials were tiredness, respiratory
tract infections, throat discomfort, headache, stomach discomfort and pain,
nausea, vomiting and diarrhoea, <a name="OLE_LINK2">increases in liver enzymes
and enzymes produced in the muscles <i>(see below)</i></a>. </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Allergic reaction </span></b></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB>These are rare (may
affect up to 1 in 1,000 people). Signs include:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.7pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>swelling of eyelids, face or
lips</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>difficulty swallowing or
breathing</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Wingdings;color:black'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=EN-GB>Contact
a doctor immediately</span></b><span lang=EN-GB> if you get these symptoms. <b>Stop
taking Lamivudine Teva</b>.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Side effects thought to be caused by Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>A very common side effect </span></b><span
lang=EN-GB>(these may affect <b>more than 1 in 10</b> people) which may show up
in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an increase in the level of some liver enzymes <i>(transaminases)</i>,
which may be a sign of inflammation or damage in the liver.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>A common side effect (</span></b><span
lang=EN-GB>these may affect<b> up to 1 in 10 </b>people) is:</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cramps and muscle pains </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.7pt;margin-bottom:
0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>skin rash or
&#8216;hives&#8217; anywhere on the body.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>A common side
effect</span></b><span lang=EN-GB> which may show up in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an increase in the level of an enzyme produced
in the muscles <i>(creatine phosphokinase)</i> which may be a sign that body
tissue is damaged.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other side effects</span></b><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Other side effects<b> </b>have
occurred in a very small number of people but their exact frequency is unknown</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breakdown of muscle tissue</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a worsening of liver disease after Lamivudine
Teva is stopped or during treatment if the hepatitis B virus becomes resistant
to Lamivudine Teva. This can be fatal in some people.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lactic acidosis <i>(see the next section,
&#8216;Other possible side effects of therapy for Hepatitis B&#8217;)</i>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A side effect which may show up in blood
tests is:</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a decrease in the number of cells involved in
blood clotting <i>(thrombocytopenia)</i>.</span></p>

<h2><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-style:normal'>If you get any side effects</span></h2>

<p class=Action style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Wingdings'>&egrave;<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><b><span lang=EN-GB>Talk
to your doctor or pharmacist. </span></b><span lang=EN-GB>This includes any
possible side effects not listed in this leaflet. </span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB
style='color:black'>Other possible side effects of therapy for Hepatitis B</span></b></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>Lamivudine Teva and related medicines (NRTIs) may cause
other conditions to develop during hepatitis B treatment.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.7pt'><b><span lang=EN-GB
style='color:black'>Lactic acidosis is a rare but serious side effect</span></b></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>Some people taking Lamivudine Teva, or other medicines like
it (NRTIs), develop a condition called lactic acidosis, together with an
enlarged liver. </span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>Lactic acidosis is caused by a build-up of lactic acid in
the body. It is rare; if it happens, it usually develops after a few months of
treatment. It can be life-threatening, causing failure of internal organs.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>Lactic acidosis is more likely to develop in people who
have liver disease, or in obese (very overweight) people, especially women.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<h3><span style='font-size:11.0pt'>Signs of lactic acidosis include:</span></h3>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>deep, rapid, difficult breathing</span></b></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>drowsiness</span></b></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>numbness</span></b><span lang=EN-GB> or <b>weakness</b>
in the limbs</span></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>feeling sick</span></b><span lang=EN-GB>
(nausea), <b>being sick</b> (vomiting) </span></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>stomach pain</span></b><span lang=EN-GB>.</span></p>

<p class=Bullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>During your treatment,
your doctor will monitor you for signs of lactic acidosis. If you have any of
the symptoms listed above, or any other symptoms that worry you:</span></p>

<p class=Action style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-21.3pt'><span lang=EN-GB
style='font-family:Wingdings'>&egrave;<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>See your doctor as soon as possible</span></b><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoFooter><b><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB style='color:red'> </span><span lang=EN-GB>This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
Lamivudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not take this medicine after the expiry date shown on the
container or carton and blister pack after EXP. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicinal product does not require any special storage conditions</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use Lamivudine Teva if you notice any change in the
appearance of the tablet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines in your wastewater or household
waste. Ask your pharmacist how to throw away medicines you no longer use. These
measures will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other</span><span lang=EN-GB>
information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine Teva contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is lamivudine. Each
film-coated tablet contains 100&nbsp;mg of lamivudine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are;<i><span
style='color:green'> </span></i></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB
style='color:black'>Tablet core: Microcrystalline cellulose, sodium starch
glycolate, magnesium stearate. Tablet film coat: Hypromellose, titanium dioxide
(E171), macrogol, polysorbate 80, iron oxide yellow (E172), iron oxide red
(E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine Teva looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=EN-GB>Orange</span><span lang=EN-GB>, capsule shaped, biconvex film-coated
tablet &#8211; engraved with &#8220;L100&#8221; on one side and plain on the
other</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Lamivudine Teva is available in aluminium blisters containing 28,
30, 84 or 100 tablets or HDPE containers containing 60 tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Not all pack sizes may beavailable in your country .</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>2031GA Haarlem</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Netherlands</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Teva Pharmaceutical Works Private Limited
Company</span></p>

<p class=MsoNormal><span lang=EN-GB>Pallagi &uacute;t 13</span></p>

<p class=MsoNormal><span lang=EN-GB>Debrecen</span><span lang=EN-GB> H-4042</span></p>

<p class=MsoNormal><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Pharmachemie B.V.</span></p>

<p class=MsoNormal><span lang=NL>Swensweg 5</span></p>

<p class=MsoNormal><span lang=NL>2031 GA Haarlem</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Teva Operations
Poland Sp.z o. o.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Mogilska 80
Str.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>31-546
Krak&oacute;w</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Poland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=535
 style='width:401.4pt;margin-left:9.0pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=DE>Belgi&euml;/Belgique/Belgien </span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Teva Pharma Belgium N.V./S.A./AG </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel/T&eacute;l: +32 38207373</span><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>UAB Teva Baltics</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +370 52660203</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b><b><span
  lang=EN-GB> </span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal;text-autospace:
  none'><span style='color:black'>&#1058;&#1077;&#1074;&#1072;</span><span
  style='color:black'> </span><span style='color:black'>&#1060;&#1072;&#1088;&#1084;&#1072;</span>
  <span lang=BG>&#1045;&#1040;&#1044;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Te</span><span
  lang=RU>&#1083;.: +</span><span lang=BG>359 2</span><span lang=EN-GB>4899585</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR style='background:yellow'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Luxembourg/Luxemburg </span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Allemagne/<b> </b>Deutschland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l/Tel: +49 73140202</span><b><span lang=EN-GB> </span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>&#268;esk&aacute; republika </span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Pharmaceuticals CR, s.r.o. </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: </span><span lang=EN-GB>+420 251007111</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Magyarorsz&aacute;g </span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva </span><span lang=EN-GB>Gy&oacute;gyszergy&aacute;r Zrt.</span><span
  lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Tel.: +36 12886400 </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b>Danmark </b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Teva
  Denmark A/S </p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tlf: +45 44985511</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Malta </span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>L-Irlanda</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +353 </span><span lang=EN-GB>19127700</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Teva GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Tel: </span><span lang=DE>+49 73140208</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE style='background:yellow'>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=NL>Nederland </span></b></p>
  <p class=MsoNormal style='margin-left:-1.15pt;line-height:normal;text-autospace:
  none'><span lang=NL>Teva Nederland B.V.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=NL>Tel: +31 8000228400 </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='color:black'>UAB </span><span style='font-family:"TimesNewRomanPSMT",serif'>Teva
  Baltics</span><span lang=EN-GB style='color:black'> Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=NL>Tel: </span><span lang=EN-GB>+372 6610801</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b>Norge</b></p>
  <p class=MsoNormal style='line-height:normal'>Teva Norway AS</p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Tlf: +47
  66775590</p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specifar
  A.B.E.E.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&#932;&#951;&#955;: +</span><span lang=EL>30 </span><span
  lang=EN-GB>2118805000</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=IS>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm Arzneimittel Vertriebs-GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Tel: +43 1970070</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Teva Pharma,
  S.L.U.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>T&eacute;l: +34 913873280</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva
  Pharmaceuticals Polska Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Tel.: +48223459300</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Sant&eacute;</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l: +33 155917800</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Pharma -
  Produtos Farmac&ecirc;uticos Lda</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Tel</span><span lang=EN-GB>: </span><span lang=EN-GB>+351
  214767550</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Pliva Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +385 13720000</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva
  Pharmaceuticals S.R.L</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +40 212306524</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: </span><span lang=EN-GB>+353 19127700 </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Pliva Ljubljana d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +386 15890390</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Finnland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Simi: +358 201805900</span><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
  Pharmaceuticals Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +421 257267911</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT-BR>Teva Italia
  S.r.l.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: </span><span lang=EN-GB>+39 028917981</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b>Suomi/Finland</b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Puh/Tel:
  +358 201805900</p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Specifar A.B.E.E.</p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&#932;&#951;&#955;: +</span><span lang=EL>30 </span><span
  lang=EN-GB>2118805000</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Teva Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Tel: +46 42121100</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>UAB </span><span style='font-family:"TimesNewRomanPSMT",serif'>Teva
  Baltics</span><span lang=EN-GB> fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +371 67323666</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva UK
  Limited</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: </span><span lang=EN-GB>+44 1977628500</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><u><span
lang=EN-GB style='color:blue'> </span></u></p>

</div>

</body>

</html>
